BioSpace News Archive

Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced the initiation of a Phase 1 clinical trial with its T cell engaging receptor IMA401 for patients with recurrent and/or refractory solid tumors.

Entrada Therapeutics, Inc. announced that Dipal Doshi, President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference.

Athenex, Inc. provided a corporate and financial update for the first quarter ended March 31, 2022.

Bioventus Inc., a global leader in innovations for active healing, reported financial results for three months ended April 2, 2022.

Akari Therapeutics, plc (Nasdaq: AKTX), a late-stage biotechnology company focused on development of advanced therapies for autoimmune and inflammatory diseases, announced positive results from the Phase II study of investigational nomacopan in bullous pemphigoid (BP) were published online in the Journal of the American Medical Association (JAMA) Dermatology.

DENTSPLY SIRONA Inc. announced its preliminary financial results for the first quarter of 2022.

Bio-Techne Corporation announced that Exosome Diagnostics, a Bio-Techne brand, will have a major scientific presence at the annual American Urological Association Conference taking place May 13-16 in New Orleans, LA.

Bausch Health Companies Inc. announced its first-quarter 2022 financial results.

Karyopharm Therapeutics Inc. announced that the Company’s senior management team will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022 at 4:35 p.m. ET in New York, NY.

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today reported financial results for the first quarter ended March 31, 2022, and highlighted recent accomplishments.